Fractures, Bone
Recent clinical, regulatory, research and industry developments relating to this disease.
Continuous operation of battery-free implants enables advanced fracture recovery monitoring.
Temporal dynamics of immune-stromal cell interactions in fracture healing.
Market withdrawal: Ibandronic Acid Sandoz (EMA)
UK clinical guideline for the prevention and treatment of osteoporosis.
Surgery versus conservative management of stable thoracolumbar fracture: the PRESTO feasibility RCT.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Ten years' experience with alendronate for osteoporosis in postmenopausal women.
Osteoporosis prevention, diagnosis, and therapy.
Marketing authorisation: Bondronat (EMA)
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials with recent milestones (1 completed or reporting results).
Clinical MilestonesViewHide
- 2026-03-06Acute Application Of Intrawound Antibiotic Powder In Open Extremity Fracture WoundsResults posted
- 2026-09-15Nonopioid Pain Control Regimen After Open Reduction and Internal Fixation of Traumatic FracturesPrimary completion
Regulatory UpdatesViewHide
- 2026-03-13Product authorisation ended — Zoledronic acidPrevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. Treatment of adult patients with tumour-induced hypercalcaemia (TIH).
- 2025-11-17Biosimilar approval — DenosumabTreatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Kefdensis significantly reduces the risk of vertebral, non-vertebral and hip fractures.Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures (see section 5.1). In men with prostate cancer receiving hormone ablation, Kefdensis significantly reduces the risk of vertebral fractures.Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture (see section 5.1).
- 2026-09-15ClinicalNonopioid Pain Control Regimen After Open Reduction and Internal Fixation of Traumatic FracturesPrimary completion
- 2026-03-13RegulatoryProduct authorisation ended — Zoledronic acidPrevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. Treatment of adult patients with tumour-induced hypercalcaemia (TIH).
- 2026-03-06ClinicalAcute Application Of Intrawound Antibiotic Powder In Open Extremity Fracture WoundsResults posted
- 2025-11-17RegulatoryBiosimilar approval — DenosumabTreatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Kefdensis significantly reduces the risk of vertebral, non-vertebral and hip fractures.Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures (see section 5.1). In men with prostate cancer receiving hormone ablation, Kefdensis significantly reduces the risk of vertebral fractures.Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture (see section 5.1).
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Product authorisation ended — Prevention of skeletal related events (pathological fractures, spinal compression, radiat… (2026)
Biosimilar approval — Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractur… (2025)
Product authorisation ended — Ibandronic acid Sandoz is indicated for the prevention of skeletal events (pathological f… (2024)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes5
- Fractures, Bone4
- Osteoporosis3
- Fracture Healing2
- Conservative Treatment1
- Prostheses and Implants1
Leading journals6
- The New England journal of medicine2
- Archives of osteoporosis1
- BioMed research international1
- Frontiers in immunology1
- Health technology assessment (Winchester, England)1
- Injury1
Leading researchers8
- Adamson J1
- Ahuja S1
- Alekseev B1
- Armstrong DJ1
- Bone HG1
- Booth A1
- Borens O1
- Bowden J1
Affiliations (unnormalised)6
- AO Research Institute Davos1
- Bio5 Institute1
- Bristol Medical School1
- Cardiff & Vale University Health Board1
- Centre for Endocrinology1
- Division of Infectious Diseases and Hospital Epidemiology1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Bone fractures are breaks in bones. The literature grounding here also treats them in the context of fragility fractures and fracture healing, including complications such as non-union and infection after fixation.
The supplied grounding does not support a specific aetiology for bone fractures beyond the fact that they are breaks in bone. It does note that fracture healing can be complicated by infection after fracture fixation, and that some fractures may fail to heal properly without intervention.
Fracture repair is described as a complex, multi-step process involving communication between immune and stromal cells to coordinate tissue repair and regeneration. The inflammatory response is necessary to initiate healing after skeletal trauma, and temporal changes in immune and stromal cell populations shape normal or delayed healing. Bone density and fracture healing are also highlighted as relevant mechanisms, and non-union reflects impaired repair.
The grounding supports osteoporosis-related fragility fracture risk in postmenopausal women and men aged 50 years and older. It also supports increased fracture risk in diabetes, where chronic hyperglycemia and related metabolic changes are associated with osteoporosis and weakened bone formation.
Management in the supplied grounding is framed around osteoporosis assessment, prevention, and treatment to prevent fragility fractures. The treatment categories mentioned include osteoporosis therapy and fracture prevention strategies, but no specific drug classes are detailed beyond the broader context of osteoporosis management. Infection after fracture fixation is recognized as a complication requiring prevention, diagnosis, and treatment in the surgical setting.
AI-generated summary grounded in MeSH and 5 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Breaks in bones.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.